HCV Treatment Guidelines
EASL 2015: New European Guidelines Prioritize Interferon-Free Hepatitis C Treatment
- Details
- Category: HCV Treatment Guidelines
- Published on Friday, 24 April 2015 00:00
- Written by Liz Highleyman
The European Association for the Study of the Liver (EASL) released its latest hepatitis C treatment guidelines at the 50th International Liver Congress taking place this week in Vienna. The guidelines recommend a variety of interferon-free direct-acting antiviral (DAA) regimens for people with hepatitis C virus genotypes 1-6. The panel offered recommendations for patient groups that remain difficult to treat, such as those with decompensated cirrhosis, but noted that more research is still needed in several areas. Also concurrent with the conference, EASL and the Latin American Association for the Study of the Liver released joint guidelines for non-invasive assessment of liver disease severity, noting that liver stiffness measurement is becoming the standard of care.
9. Evolving Hepatitis C Therapy Guidelines and Treatment Cascade
- Details
- Category: HCV Treatment
- Published on Monday, 12 January 2015 00:00
- Written by HIVandHepatitis.com
The first U.S. hepatitis C treatment guidelines incorporating interferon-free direct-acting antiviral regimens were issued in January 2014 and periodically updated to reflect new drug approvals and emerging data from studies and real-world use. The new therapies have cure rates above 90%, but cost and other barriers have limited their use.
New Hepatitis C Guidelines: Who Should Be Treated and When?
- Details
- Category: HCV Treatment Guidelines
- Published on Tuesday, 12 August 2014 00:00
- Written by Liz Highleyman
Everyone with chronic hepatitis C could potentially benefit from treatment with new direct-acting antivirals, but when resources are limited, people with advanced liver disease, those at greatest risk for complications, and those most likely to transmit HCV should be treated most urgently, according to new guidelines released this week from AASLD, IDSA, and IAS-USA.
Updated Hepatitis C Treatment Guidelines Add New Therapies, Hard-to-Treat Patients
- Details
- Category: HCV Treatment Guidelines
- Published on Monday, 12 January 2015 00:00
- Written by Liz Highleyman
The American Association for the Study of Liver Diseases (AASLD), Infectious Diseases Society of America (IDSA), and International Antiviral Society-USA (IAS-USA) recently updated their hepatitis C treatment guidelines to add newly approved interferon-free direct-acting antiviral regimens and to provide more information about treating patients with HIV/HCV coinfection and decompensated liver disease. The evolving guidelines are available online at HCVguidelines.org.
EASL 2014: European Liver Specialists Recommend Use of Newest Hepatitis C Drugs
- Details
- Category: HCV Treatment Guidelines
- Published on Saturday, 12 April 2014 00:00
- Written by Keith Alcorn
The European Association for the Study of the Liver (EASL) has issued new guidelines for the treatment of hepatitis C, which recommend that wherever possible, patients should be treated with the newest direct-acting antivirals. The guidelines also recommend physicians should "mix and match" antivirals from different companies to get the most potent regimens.
More Articles...
- EASL 2014: WHO Recommends Global Use of Newest Hepatitis C Drugs, Urges Price Reductions
- Advances in Hepatitis C Treatment: the Future Is Now [VIDEO]
- CROI 2014/APASL 2014: Merck Combo Suppresses HCV in Monoinfected and Coinfected Patients
- AASLD, IDSA & IAS-USA Announce New Hepatitis C Treatment Guidelines